Sustained Release of Multiple Growth Factors from Injectable Polymeric System as a Novel Therapeutic Approach Towards Angiogenesis

PurposeThe aim was to investigate that a bio-degradable alginate and poly lactide-co-glycolide (PLG) system capable of delivering growth factors sequentially would be superior to single growth factor delivery in promoting neovascularization and improving perfusion.MethodsThree groups of apoE null mice underwent unilateral hindlimb ischemia surgery and received ischemic limb intramuscular injections of alginate (Blank), alginate containing VEGF165 (VEGF), or alginate containing VEGF165 combined with PLG microspheres containing PDGF-BB (VEGF/PDGF). Vascularity in the ischemic hindlimb was assessed by morphologic and immunohistochemical end-points, while changes in blood flow were assessed by Laser Doppler Perfusion Index. Muscle VEGF and PDGF content was assessed at multiple time points.ResultsIn the VEGF/PDGF group, local tissue VEGF and PDGF levels peaked at week 2 and 4, respectively, with detectable PDGF levels at week 6. At week 6, mean vessel mean diameter was significantly greater in the VEGF/PDGF group compared to the VEGF or Blank groups with evidence of well-formed smooth muscle-lined arterioles.ConclusionsSequential delivery of VEGF and PDGF using an injectable, biodegradable platform resulted in stable and sustained improvements in perfusion. This sustained, control-released, injectable alginate polymer system is a promising approach for multiple growth factor delivery in clinical application.

[1]  David J Mooney,et al.  Cell delivery mechanisms for tissue repair. , 2008, Cell stem cell.

[2]  J. Isner,et al.  Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice. , 1999, Circulation.

[3]  J. Hartikainen,et al.  Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT) , 2003, Circulation.

[4]  Michael C. Ostrowski,et al.  Ambient Air Pollution Exaggerates Adipose Inflammation and Insulin Resistance in a Mouse Model of Diet-Induced Obesity , 2009, Circulation.

[5]  S. Rajagopalan,et al.  Management of chronic critical limb ischemia. , 2002, Cardiology clinics.

[6]  S. Rajagopalan,et al.  Sustained Vascular Endothelial Growth Factor Delivery Enhances Angiogenesis and Perfusion in Ischemic Hind Limb , 2005, Pharmaceutical Research.

[7]  Brian H Annex,et al.  The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .

[8]  R. K. Jain,et al.  Vessels of death or life. , 2001, Scientific American.

[9]  J. Isner,et al.  Therapeutic Angiogenesis for Coronary Artery Disease , 2002, Annals of Internal Medicine.

[10]  D. Mooney,et al.  Injectable Hydrogels Providing Sustained Delivery of Vascular Endothelial Growth Factor are Neuroprotective in a Rat Model of Huntington’s Disease , 2009, Neurotoxicity Research.

[11]  S M Jorgensen,et al.  Three-dimensional imaging of vasculature and parenchyma in intact rodent organs with X-ray micro-CT. , 1998, The American journal of physiology.

[12]  P. Serruys,et al.  Geographical miss and restenosis during catheter-based intracoronary beta-radiation for de novo lesions. , 2002, Cardiovascular radiation medicine.

[13]  R. Laham.  Angiogenesis (clinical trials). , 2001, The Canadian journal of cardiology.

[14]  Armin Helisch,et al.  Arteriogenesis The Development and Growth of Collateral Arteries , 2003, Microcirculation.

[15]  David J. Mooney,et al.  Growth Factors, Matrices, and Forces Combine and Control Stem Cells , 2009, Science.

[16]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[17]  D. Mooney,et al.  Tissue engineering strategies for in vivo neovascularisation , 2002, Expert opinion on biological therapy.

[18]  F. Sellke,et al.  Therapeutic angiogenesis in cardiology using protein formulations. , 2001, Cardiovascular research.

[19]  David J Mooney,et al.  Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. , 2007, Cardiovascular research.

[20]  J. Ware,et al.  Therapeutic angiogenesis in cardiovascular disease , 2003, Nature Reviews Drug Discovery.

[21]  P. Carmeliet,et al.  Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.

[22]  M. Nagai,et al.  Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers , 2002, Expert opinion on biological therapy.

[23]  R Langer,et al.  Localized delivery of epidermal growth factor improves the survival of transplanted hepatocytes , 1996, Biotechnology and bioengineering.

[24]  David J Mooney,et al.  New materials for tissue engineering: towards greater control over the biological response. , 2008, Trends in biotechnology.

[25]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.

[26]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.